Lupus Nephritis
CAR T-cell therapy may be a ‘miracle,’ but it is too soon to say ‘cure’
It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.
SGLT2 inhibitors slash risks for lupus nephritis, heart failure in SLE, type 2 diabetes
Treatment with sodium-glucose cotransporter-2 inhibitors significantly lowered risks for lupus nephritis, dialysis and kidney transplant for patients with systemic lupus erythematosus and type 2 diabetes, according to data.
Patient with lupus treated with KYV-101 CAR T-cell therapy relapses after 5 months
A patient with lupus nephritis treated with KYV-101, a chimeric antigen receptor T-cell immunotherapy, saw their disease return 5 months after initially showing a response to the treatment, according to the manufacturer.
Top in rheumatology: Steroid dosing for lupus nephritis; Benlysta decreases lupus flares
A systemic review and meta-analysis revealed that higher initial glucocorticoid doses improved lupus nephritis treatment response but increased risks for serious infections and mortality.
Higher steroid dose improves lupus nephritis renal outcomes, raises mortality risk
Patients with lupus nephritis who receive higher initial doses of glucocorticoids demonstrate improved renal outcomes, albeit with increased serious infection and mortality risks, according to data published in Arthritis & Rheumatology.
Serology ‘significantly different’ between membranous vs. proliferative lupus nephritis
Proteinuria levels are not predictive of membranous lupus nephritis vs. proliferative lupus nephritis, according to data published in Rheumatology.
'Quelling anxiety' essential for rheumatologists ensuring safe pregnancies
DESTIN, Fla. — Ongoing, frank discussions about reproductive health with patients of childbearing age is critical to safe pregnancy outcomes, according to a presenter at the Congress of Clinical Rheumatology East.
FDA approves updated label for Lupkynis with long-term data, new monitoring guidelines
The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments.
Urticarial Vasculitis, Part 2: Walking the Balance Beam of Allergy and Rheumatology
This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.
FDA clears new drug application for CAR T-cell therapy in SLE with lupus nephritis
The FDA has cleared an investigational new drug application for an allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of systemic lupus erythematosus with lupus nephritis, according to the manufacturer.